Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 51-58

  Theile, Dirk ^a   Detering, Jan Christoph ^a   Herold Mende, Christel ^a   Dyckhoff, Gerhard ^a   Haefeli, Walter E ^a   Weiss, Johanna ^a   Burhenne, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; HUMAN COPPER TRANSPORTER 1; MENKES PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OXALIPLATIN; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

ABCC2 GENE; ACCURACY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATP7A GENE; ATP7B GENE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG UPTAKE; GENE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SLC22A1 GENE; SLC22A2 GENE; SLC31A1 GENE; SQUAMOUS CELL CARCINOMA; TANDEM MASS SPECTROMETRY;

AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CYTOSTATIC AGENTS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PLATINUM; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84858634036     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189621     Document Type: Article

References (39)

1. Aggarwal SK, Gemma NW, Kinter M, Nicholson J, Shipe JR Jr, and Herold DA (1993) Determination of platinum in urine, ultrafiltrate, and whole plasma by isotope dilution gas chromatography-mass spectrometry compared to electrothermal atomic absorption spectrometry. Anal Biochem 210:113-118. (Pubitemid 23147941)
2. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, and Weiss J (2005) Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 70:949-958. (Pubitemid 41138860)
3. Arnould S, Hennebelle I, Canal P, Bugat R, and Guichard S (2003) Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112-119. (Pubitemid 36005433)
4. Bond AM and Martin RL (1984) Electrochemistry and redox behaviour of transition metal dithiocarbamates. Coord Chem Rev 54:23-98.
5. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, and Wiemer EA (2010) Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898-908.
6. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, and Clerico M (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526. (Pubitemid 24223504)
7. Colevas AD (2006) Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24:2644-2652.
8. Cui Y, König J, Buchholz JK, Spring H, Leier I, and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937. (Pubitemid 29214613)
9. Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, and Brienza S (1996) Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 32B:278-279.
10. Drummer OH, Proudfoot A, Howes L, and Louis WJ (1984) High-performance liquid chromatographic determination of platinum (II) in plasma ultrafiltrate and urine: comparison with a flameless atomic absorption spectrometric method. Clin Chim Acta 136:65-74. (Pubitemid 14213322)
11. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, and Van Echo D (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4:1506-1509. (Pubitemid 17183575)
12. Fanucchi M and Khuri FR (2004) Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 31:809-815. (Pubitemid 39602687)
13. Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, and Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 50:7887-7894.
14. Fisch MJ, Howard KL, Einhorn LH, and Sledge GW (1996) Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 2:1063-1066. (Pubitemid 26198476)
15. Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RC, and Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270-2274. (Pubitemid 28240836)
16. Freier K, Hofele C, Knoepfle K, Gross M, Devens F, Dyckhoff G, Plinkert P, Lichter P, and Herold-Mende C (2010) Cytogenetic characterization of head and neck squamous cell carcinoma cell lines as model systems for the functional analyses of tumor-associated genes. J Oral Pathol Med 39:382-389.
17. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, and Bryson P (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14:195-208.
18. Goodisman J, Hagrman D, Tacka KA, and Souid AK (2006) Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 57:257-267. (Pubitemid 41779846)
19. Goodwin RA and Asmis TR (2009) Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg 22:251-256.
20. Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, and Defazio A (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100:239-246. (Pubitemid 43075256)
21. Hoffman HT, Karnell LH, Funk GF, Robinson RA, and Menck HR (1998) The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 124:951-962. (Pubitemid 28411496)
22. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, and Schacter L (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263.
23. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25:402-408. (Pubitemid 34164012)
24. Lloyd JR and Hess S (2009) A corona discharge initiated electrochemical electrospray ionization technique. J Am Soc Mass Spectrom 20:1988-1996.
25. Minakata K, Nozawa H, Okamoto N, and Suzuki O (2006) Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 832:286-291. (Pubitemid 43339960)
26. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, and Herold-Mende C (2003) Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106:34-44. (Pubitemid 36750385)
27. Peters T, Lindenmaier H, Haefeli WE, and Weiss J (2006) Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 372:291-299. (Pubitemid 43119563)
28. Rabik CA and Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23. (Pubitemid 46137553)
29. Raghavan R, Burchett M, Loffredo D, and Mulligan JA (2000) Low-level (PPB) determination of cisplatin in cleaning validation (rinse water) samples. II. A high-performance liquid chromatographic method. Drug Dev Ind Pharm 26:429-440. (Pubitemid 30207715)
30. Safaei R and Howell SB (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:13-23. (Pubitemid 39656107)
31. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, and Verweij J (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569-1575. (Pubitemid 26235386)
32. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, and Kuwano M (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124-4129. (Pubitemid 26305002)
33. Theile D, Grebhardt S, Haefeli WE, and Weiss J (2009) Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 78:1366-1373.
34. Theile D, Ketabi-Kiyanvash N, Herold-Mende C, Dyckhoff G, Efferth T, Bertholet V, Haefeli WE, and Weiss J (2011) Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck 33:959-968.
35. Van Berkel GJ and Kertesz V (2007) Using the electrochemistry of the electrospray ion source. Anal Chem 79:5510-5520. (Pubitemid 47229794)
36. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, Looijenga LH, Scheper R, van der Wal JE, Menkema L, et al. (2009) Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124:2643-2650.
37. Verschraagen M, Kedde MA, Hausheer FH, and Van Der Vijgh WJ (2003) The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer Chemother Pharmacol 51:499-504. (Pubitemid 36791676)
38. Welters MJ, Fichtinger-Schepman AM, Baan RA, Hermsen MA, van der Vijgh WJ, Cloos J, and Braakhuis BJ (1997) Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 71:410-415. (Pubitemid 27224306)
39. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847-8857. (Pubitemid 44449203)